NZ620263B2 - 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor - Google Patents
4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor Download PDFInfo
- Publication number
- NZ620263B2 NZ620263B2 NZ620263A NZ62026312A NZ620263B2 NZ 620263 B2 NZ620263 B2 NZ 620263B2 NZ 620263 A NZ620263 A NZ 620263A NZ 62026312 A NZ62026312 A NZ 62026312A NZ 620263 B2 NZ620263 B2 NZ 620263B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- pharmaceutically acceptable
- cancer
- formula
- acceptable salt
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title claims abstract description 51
- 108050009021 Bromodomains Proteins 0.000 title claims abstract description 50
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 40
- 239000003112 inhibitor Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 239000011780 sodium chloride Substances 0.000 claims abstract description 110
- 150000003839 salts Chemical class 0.000 claims abstract description 104
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 230000001684 chronic Effects 0.000 claims abstract description 8
- 230000001363 autoimmune Effects 0.000 claims abstract description 6
- 230000004968 inflammatory condition Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 64
- -1 4-(8-methoxy(1-methoxypropanyl) (tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole Chemical compound 0.000 claims description 55
- 201000010099 disease Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 206010024324 Leukaemias Diseases 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 201000009251 multiple myeloma Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 201000009030 carcinoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 201000004253 NUT midline carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 241000838195 Frommia Species 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical class CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000000634 powder X-ray diffraction Methods 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 230000002829 reduced Effects 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- 210000004027 cells Anatomy 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 238000007792 addition Methods 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000001154 acute Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- 102100015499 BRD2 Human genes 0.000 description 6
- 101700003936 BRD2 Proteins 0.000 description 6
- 102100015498 BRD3 Human genes 0.000 description 6
- 101700008396 BRD3 Proteins 0.000 description 6
- 102100015500 BRD4 Human genes 0.000 description 6
- 101700009767 BRD4 Proteins 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000002209 hydrophobic Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010874 syndrome Diseases 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 210000003483 Chromatin Anatomy 0.000 description 5
- NNJPGOLRFBJNIW-HNNXBMFYSA-N Demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- 102000006947 Histones Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 230000001973 epigenetic Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 230000000699 topical Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 208000001756 Virus Disease Diseases 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002757 inflammatory Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940011051 isopropyl acetate Drugs 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000007514 Herpes Zoster Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 210000001623 Nucleosomes Anatomy 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 206010047461 Viral infection Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002440 hepatic Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 230000002103 transcriptional Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 238000000836 variable-temperature nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- 206010069351 Acute lung injury Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000002847 Cowden syndrome Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 206010067410 Endotoxaemia Diseases 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 206010061255 Ischaemia Diseases 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000004644 Retinal Vein Occlusion Diseases 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 206010040070 Septic shock Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000000389 T-Cell Leukemia Diseases 0.000 description 2
- 238000010928 TGA analysis Methods 0.000 description 2
- 206010043207 Temporal arteritis Diseases 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 230000035507 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 201000005569 gout Diseases 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 1
- HPXNTHKXCYMIJL-UHFFFAOYSA-N 1,1'-bis(diphenylphosphanyl)ferrocene Chemical compound C12C3C4C5[Fe]4322346(C7(C2C6C4C37)P(C=2C=CC=CC=2)C=2C=CC=CC=2)C15P(C=1C=CC=CC=1)C1=CC=CC=C1 HPXNTHKXCYMIJL-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KNYKHCLCBHSFCK-UHFFFAOYSA-N 1-methoxypropan-1-amine Chemical compound CCC(N)OC KNYKHCLCBHSFCK-UHFFFAOYSA-N 0.000 description 1
- FWFUSMMVFVVERM-UHFFFAOYSA-N 2-(1,4-dioxan-2-yl)acetic acid Chemical compound OC(=O)CC1COCCO1 FWFUSMMVFVVERM-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2H-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N AcOH acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010000860 Acute megakaryocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001019 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 241001088417 Ammodytes americanus Species 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000288575 Astomaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010069664 Atopic keratoconjunctivitis Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010072959 Birdshot chorioretinopathy Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091005571 Bromodomain-containing proteins Proteins 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010051906 Cowden's disease Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 206010015281 Erythroleukaemia Diseases 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N Et3N triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N Europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102100002658 H2BS1 Human genes 0.000 description 1
- 101700021312 H2BS1 Proteins 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N HCl HCl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 206010023125 Jarisch-Herxheimer reaction Diseases 0.000 description 1
- 201000007313 Kawasaki disease Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- 229960001375 Lactose Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229960001021 Lactose Monohydrate Drugs 0.000 description 1
- 208000009503 Leukemia, Erythroblastic, Acute Diseases 0.000 description 1
- 208000006695 Leukemia, Megakaryoblastic, Acute Diseases 0.000 description 1
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 208000000015 Leukemia, Neutrophilic, Chronic Diseases 0.000 description 1
- 208000005749 Leukemia, Promyelocytic, Acute Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010071392 Macular fibrosis Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 206010025425 Maculopathy Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 235000016247 Mentha requienii Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940093918 Quinoline gynecological antiinfectives Drugs 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229940005581 Sodium Lactate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940100611 Topical Cream Drugs 0.000 description 1
- 229940042130 Topical Foam Drugs 0.000 description 1
- 229940042129 Topical Gel Drugs 0.000 description 1
- 229940100615 Topical Ointment Drugs 0.000 description 1
- 229940041677 Topical Spray Drugs 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010057435 Vitreous adhesions Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N XANTHOTOXIN Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108091005638 acetylated proteins Proteins 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic Purine analogs Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites Pyrimidine analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027991 antiseptics and disinfectants Quinoline derivatives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- SATZVFKUEAMFPB-UHFFFAOYSA-N azanium;sodium;chloride Chemical compound [NH4+].[Na].[Cl-] SATZVFKUEAMFPB-UHFFFAOYSA-N 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000006682 bigleaf mint Nutrition 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000006322 bullous skin disease Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical class CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000006082 chickenpox Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035510 distribution Effects 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004052 folic acid antagonist Chemical class 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000006679 mint Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 201000002165 neuroretinitis Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- CDKSDHJUTXTPHO-UHFFFAOYSA-N oxane-2-carbonyl chloride Chemical compound ClC(=O)C1CCCCO1 CDKSDHJUTXTPHO-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000007407 panuveitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004977 physiological function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920003245 polyoctenamer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000010741 protein sumoylation Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N stearylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Provided is the compound 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole or a salt thereof. The compound is a bromodomain inhibitor. The compound is useful in the treatment of cancer and chronic autoimmune and/or inflammatory conditions. conditions.
Description
-(8-M ETHOXY((1-M ETHOXYPROPANYL)(TETRAHYDRO-2H-PYRANYL)-1 H-I MIDAZO [4,5-C]
QUINOLINYL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN TOR
Field of the Invention
The present invention relates to novel compounds, pharmaceutical compositions
containing such compounds and to their use in therapy.
Background of the ion
The genomes of eukaryotic organisms are highly organised within the s of
the cell. The long strands of duplex DNA are wrapped around an octomer of histone
ns (most usually comprising two copies of histones H2A, H2B H3 and H4) to form a
nucleosome. This basic unit is then further compressed by the aggregation and folding of
nucleosomes to form a highly condensed tin structure. A range of different states
of condensation are possible, and the tightness of this structure varies during the cell
cycle, being most compact during the process of cell division. Chromatin structure plays a
critical role in regulating gene transcription, which cannot occur ently from highly
condensed chromatin. The chromatin structure is controlled by a series of post
translational modifications to histone proteins, y histones H3 and H4, and most
commonly within the histone tails which extend beyond the core nucleosome structure.
These modifications include acetylation, methylation, phosphorylation, ubiquitinylation,
SUMOylation. These epigenetic marks are written and erased by specific enzymes, which
place the tags on specific residues within the histone tail, thereby forming an epigenetic
code, which is then interpreted by the cell to allow gene specific regulation of chromatin
structure and thereby transcription.
Histone acetylation is most usually associated with the activation of gene
ription, as the modification loosens the interaction of the DNA and the histone
octomer by changing the electrostatics. In on to this physical change, specific
proteins bind to acetylated lysine es within histones to read the epigenetic code.
Bromodomains are small (~110 amino acid) ct s within proteins that bind to
acetylated lysine resides commonly but not exclusively in the t of histones. There is
a family of around 50 proteins known to n bromodomains, and they have a range of
functions within the cell.
The BET family of bromodomain containing proteins comprises 4 proteins (BRD2,
BRD3, BRD4 and BRD-t) which contain tandem bromodomains capable of binding to two
acetylated lysine residues in close proximity, increasing the specificity of the interaction.
BRD2 and BRD3 are reported to associate with histones along actively transcribed genes
and may be involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell. 2008
51-60), while BRD4 appears to be involved in the recruitment of the pTEF-B
complex to inducible genes, resulting in phosphorylation of RNA polymerase and
increased transcriptional output (Hargreaves et al, Cell, 2009 138(1): 129-145). It has also
been reported that BRD4 or BRD3 may fuse with NUT (nuclear protein in ) forming
novel fusion oncogenes, BRD4-NUT or BRD3-NUT, in a highly malignant form of
40 epithelial neoplasia (French et al. Cancer Research, 2003, 63, 7 and French et al.
Journal of Clinical Oncology, 2004, 22 (20), 4135-4139). Data ts that BRD-NUT
fusion proteins contribute to carcinogenesis (Oncogene, 2008, 27, 2237-2242). BRD-t is
uniquely expressed in the testes and ovary. All family members have been reported to
have some function in controlling or executing aspects of the cell cycle, and have been
shown to remain in complex with chromosomes during cell division — suggesting a role in
the maintenance of epigenetic . In addition some viruses make use of these
proteins to tether their genomes to the host cell chromatin, as part of the process of viral
replication (You et al Cell, 2004 117(3):349—60).
se patent application JP2008—156311 discloses a benzimidazole derivative
which is said to be a BRD2 bromodomain binding agent which has utility with respect to
virus infection / proliferation.
Patent application W02009084693A1 discloses a series of
triazolodiazepiene derivatives that are said to inhibit the binding n an
acetylated histone and a bromodomain containing protein which are said to be useful as
anti-cancer agents.
Patent application W02011/054846 discloses a series of quinoline derivatives that
inhibit the binding of BET family bromodomains with acetylated lysine residues.
Novel compounds have been found which inhibit the binding of bromodomains
with its cognate acetylated proteins, more particularly a class of compounds that inhibit
the binding of BET family bromodomains to acetylated lysine residues. Such compounds
will ter be referred to as “bromodomain tors”.
Summam of the Invention
In a first aspect of the present invention, there is provided a nd of formula
(I) or a salt thereof, more particularly a compound of formula (I) or a pharmaceutically
able salt thereof
| N
In a second aspect of the present invention, there is provided a pharmaceutical
composition comprising a compound of formula (I) or a pharmaceutically acceptable salt
thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
In a third aspect of the present invention, there is provided a compound of formula
(I), or a pharmaceutically acceptable salt thereof for use in therapy, in particular in the
ent of diseases or conditions for which a bromodomain inhibitor is indicated.
In a fourth aspect of the present invention, there is provided a method of treating
diseases or conditions for which a bromodomain tor is indicated in a subject in need
thereof which ses administering a therapeutically ive amount of a compound
of formula (I) or a pharmaceutically acceptable salt thereof.
In a fifth aspect of the t invention, there is provided the use of a compound
of a (I), or a pharmaceutically acceptable salt thereof in the manufacture of a
medicament for the ent of es or conditions for which a bromodomain inhibitor
is indicated.
Brief ption of the Figures
Figure 1: Shows an XRPD pattern of a crystalline form of 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole (anhydrous form 1).
Figure 2: Shows an XRPD pattern of a crystalline form of 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole (anhydrous form 2).
Figure 3: Shows an XRPD pattern of a crystalline form of 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole (anhydrous form 3).
Figure 4: Shows an XRPD pattern of a crystalline form of 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole (hydrate).
Figure 5: Shows an XRPD pattern of a crystalline form of 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
ylisoxazole hydrochloride (hydrochloride).
Detailed Description of the Invention
The present ion relates to a compound of formula (I) which is 4-(8-methoxy(1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole
or a salt f
The compound of a (I) contains a chiral atom such that optical isomers, e.g.
enantiomers may be formed. Accordingly, the present invention encompasses all isomers
of the compound of formula (I) whether as individual isomers isolated such as to be
substantially free of the other isomer (i.e. pure) or as mixtures (i.e. racemates and racemic
mixtures). An individual isomer isolated such as to be substantially free of the other
isomer (i.e. pure) may be isolated such that less than 10%, particularly less than about
1%, for example less than about 0.1% of the other isomer is present.
Separation of isomers may be achieved by conventional techniques known to
those d in the art, e.g. by fractional crystallisation, chromatography or HPLC.
In one embodiment there is provided a compound of a (IA) which is 4-(8-
methoxy((R)methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-
WO 24104
c]quinolinyl)—3,5-dimethylisoxazole
(IA)
or a salt thereof.
In a further embodiment there is provided a compound of formula (IB) which is 4-
(8-methoxy((S)methoxypropanyl)(tetrahydro-2H-pyranyl)-1 H-imidazo[4,5-
c]quinolinyl)—3,5-dimethylisoxazole
(“3)
or a salt thereof.
It will be appreciated that the compounds of formula (IA) and formula (IB) are
within the scope of the compound of formula (I). As used , unless otherwise stated,
a reference to a compound of formula (I) also includes a nce a the compound of
formula (IA) and a compound of formula (IB).
It will be appreciated that the present invention covers compounds of formula (I) as
the free base and as salts f, for example as a pharmaceutically acceptable salt
thereof. In one embodiment the ion relates to compounds of a (I) in the form
of a free base. In one embodiment the invention relates to compounds of formula (I) or a
pharmaceutically acceptable salt thereof.
Because of their potential use in medicine, salts of the compounds of formula (I)
are desirably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts
can include acid addition salts. For a review of suitable pharmaceutically acceptable salts
see Berge et al., J. Pharm. Sci., 66:1-19, (1977). Typically, a pharmaceutically acceptable
salt may be readily prepared by using a desired acid or base as appropriate. The
resultant salt may precipitate from solution and be collected by filtration or may be
recovered by evaporation of the t.
A pharmaceutically acceptable acid addition salt can be formed by reaction of a
compound of formula (I) with a le inorganic or organic acid (such as hydrobromic,
hydrochloric, sulphuric, nitric, phosphoric, succinic, , acetic, propionic, fumaric,
citric, tartaric, lactic, benzoic, salicylic, glutamaic, aspartic, p-toluenesulfonic,
benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-
naphthalenesulfonic, or hexanoic acid), optionally in a suitable solvent such as an organic
solvent, to give the salt which is usually isolated for example by crystallisation and
filtration or by evaporation followed by trituration. A pharmaceutically acceptable acid
addition salt of a compound of formula (I) can comprise or be for example a
hydrobromide, hydrochloride, sulfate, e, phosphate, succinate, maleate, acetate,
propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate,
p-toluenesulfonate, benzenesulfonate, esulfonate, ethanesulfonate,
alenesulfonate (e.g. 2—naphthalenesulfonate) or hexanoate salt. In one
embodiment a pharmaceutically able acid addition salt of a compound of formula (I)
can comprise or be a hloride, sulfate, maleate, fumarate, citrate, p-
toluenesulfonate, benzenesulfonate or esulfonate salt. In a particular embodiment
there is ed a compound of formula (IA) in the form of a hydrochloride salt.
Other non-pharmaceutically acceptable salts, e.g. formates, oxalates or
trifluoroacetates, may be used, for example in the isolation of the compounds of formula
(I), and are included within the scope of this invention.
The invention includes within its scope all possible stoichiometric and non-
stoichiometric forms of the salts of the compounds of formula (I).
It will be appreciated that many organic compounds can form complexes with
solvents in which they are d or from which they are precipitated or crystallized.
These complexes are known as “solvates”. For example, a complex with water is known
as a “hydrate”. Solvents with high boiling points and/or capable of forming hydrogen
bonds such as water, , N-methyl pyrrolidinone, methanol and ethanol may be used
to form solvates. Methods for identification of solvates include, but are not limited to,
NMR and microanalysis. Solvates of the nds of formula (I) are within the scope of
the invention.
The invention includes within its scope all possible stoichiometric and non-
stoichiometric forms of the solvates of the compounds of formula (I).
The invention encompasses all prodrugs, of the compound of formula (I) or a
pharmaceutically able salt f, which upon administration to the recipient is
capable of providing (directly or indirectly) the compound of a (I) or a
pharmaceutically able salt thereof, or an active lite or residue thereof.
Such derivatives are recognizable to those skilled in the art, without undue
experimentation. Nevertheless, reference is made to the teaching of ’s Medicinal
Chemistry and Drug Discovery, 5th n, Vol 1: Principles and Practice, which is
orated herein by reference to the extent of teaching such derivatives.
The compounds of formula (I) may be in crystalline or amorphous form.
Furthermore, some of the crystalline forms of the compounds of formula (I) may exist as
40 polymorphs, which are included within the scope of the present invention. Polymorphic
forms of compounds of a (I) may be characterized and entiated using a
number of conventional analytical techniques, including, but not limited to, X-ray powder
diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning
calorimetry (DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic
resonance (SSNMR).
The nd of a (IA), that is to say 4-(8-methoxy((R)—1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)—3,5—
dimethylisoxazole, in the form of a free base has been found to exist in a number of
different crystalline forms, namely, anhydrous forms 1, 2 and 3 and hydrated form 1.
Such crystalline forms can be prepared by procedures described herein.
Thus in one embodiment, there is provided a crystalline form of 4-(8-methoxy
-methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5—c]quinolinyl)—
methylisoxazole (anhydrous form 1) characterised by substantially the X-ray
powder diffraction (XRPD) pattern as shown in Figure 1, wherein the XRPD pattern is
expressed in terms of 2 theta angles and obtained with a diffractometer using copper
Ker-radiation using procedures described . The XRPD pattern of anhydrous form 1
shows characteristic 2 theta angle peaks as listed in Example 9 Table 1.
In a further embodiment, there is provided a crystalline form of 4-(8—methoxy
((R)—1-methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5—c]quinolinyl)—
3,5-dimethylisoxazole (anhydrous form 2) characterised by substantially the X-ray
powder diffraction (XRPD) pattern as shown in Figure 2, wherein the XRPD pattern is
expressed in terms of 2 theta angles and obtained with a diffractometer using copper
Ker-radiation using procedures described. The XRPD pattern of anhydrous form 2 shows
characteristic 2 theta angle peaks as listed in Example 9 Table 1.
In a further embodiment, there is provided a crystalline form 4-(8—methoxy((R)—
1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)—3,5-
dimethylisoxazole (anhydrous form 3) terised by substantially the X-ray powder
diffraction (XRPD) pattern as shown in Figure 3, wherein the XRPD pattern is expressed
in terms of 2 theta angles and obtained with a ctometer using copper Kor-radiation
using procedures described herein. The XRPD pattern of anhydrous form 3 shows
characteristic 2 theta angle peaks as listed in Example 9 Table 1.
In a further embodiment, there is ed a lline form of 4-(8—methoxy
((R)—1-methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5—c]quinolinyl)—
3,5-dimethylisoxazole (hydrate) terised by substantially the X—ray powder
diffraction (XRPD) pattern as shown in Figure 4, wherein the XRPD pattern is expressed
in terms of 2 theta angles and obtained with a diffractometer using copper Kor-radiation
using procedures described herein. The XRPD pattern of the hydrate shows
characteristic 2 theta angle peaks as listed in Example 9 Table 1.
The ion also provides for the compound of formula (IA) that is to say 4-(8—
methoxy((R)—1-methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-
c]quinolinyl)—3,5—dimethylisoxazole hydrochloride in crystalline form. Such a crystalline
form can be prepared by procedures described herein.
40 In a r embodiment, there is provided a crystalline form of 4-(8—methoxy
-methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5—c]quinolinyl)—
3,5-dimethylisoxazole hydrochloride (hydrochloride form 1) characterised by
substantially the X-ray powder diffraction (XRPD) pattern as shown in Figure 5, wherein
the XRPD pattern is expressed in terms of 2 theta angles and obtained with a
diffractometer using copper Kor-radiation using procedures described herein. The XRPD
pattern of this form shows teristic 2 theta angle peaks as listed in Example 9
Table 1.
It will be appreciated from the foregoing that included within the scope of the
invention are solvates, s and polymorphic forms of the compounds of formula (I)
and salts thereof.
The nds of a (I) or salts thereof may be made by a variety of
methods, including rd chemistry. rative general synthetic methods are set out
below and then specific compounds of formula (I) and pharmaceutically acceptable salts
thereof, are prepared in the Examples.
The compound of formula (I) can be prepared from the compound of a (II)
by, for example, heating the compound of formula (II) in acetic acid or p-toluenesulfonic
acid in toluene
(II)
The compound of formula (II) can be prepared by reaction of the compound of
formula (III)
(III)
with a compound of formula (IV) or an activated derivative thereof
(IV)
A suitable activated derivative of the compound of formula (IV) is the acid chloride.
The reaction between the compound of formula (III) and compound of formula (IV) may be
carried out in a le organic solvent optionally in the presence of a base.
Where the compound of a (I) is a mixture of isomers the compounds of
formula (IA) and formula (IB) can be obtained from the compound of formula (I) using
suitable separation ques which are familiar to those skilled in the art, such as those
described herein. Alternatively the compounds of formula (IA) and (IB) may be prepared
by a chiral synthesis procedure. By way of illustration, the compound of formula (IA) may
be prepared by the procedure set out in Scheme 1.
Scheme 1
1.2.5M BuLi
2. B(Oi-Pr)3 (I)
:1 g J£>\NO2N SnCI2 2H20,
/ Br 0J1I B(OH)2 EtOH
N 3. HO OH N
/ / _.
0 —’
NH 2
Pd(dppf)2C|2 No’ /
t I
C02Et (I) o\L HCI
POCI NH2
N , / MyC02Et _, _.
0 N
C02Et ~130 c
o MeCN,K2C03
~85 °c
LiOH,
CO2Et MeOH/HZO
| OMe
IPEA L H o
LiOH, H20 l DCM Dim;
fl —>
o 0 (%l o
L 1)DCM,K2CO3 N
| N o HCI/MeOH o 2)i—PrOAc
o NH2
\ /
N / N
/ /
\ N b
It will be appreciated by those skilled in the art that it may be advantageous to
t one or more functional groups of the nds described above. Examples of
protecting groups and the means for their removal can be found in T. W. Greene
‘Protective Groups in Organic sis’ (4th edition, J. Wiley and Sons, 2006). Suitable
amine protecting groups include acyl (e.g. acetyl, carbamate (e.g. 2’,2’,2’-
trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g.
benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric
acid in dioxane or trifluoroacetic acid in dichloromethane) or reductively (e.g.
hydrogenolysis of a benzyl or benzyloxycarbonyl group or reductive removal of a 2’-
trichloroethoxycarbonyl group using zinc in acetic acid) as riate. Other suitable
amine protecting groups include trifluoroacetyl (-COCF3) which may be removed by base
catalysed hydrolysis.
It will be appreciated that in any of the routes described above, the precise order of
the synthetic steps by which the various groups and moieties are introduced into the
molecule may be varied. It will be within the skill of the practitioner in the art to ensure
that groups or moieties introduced at one stage of the process will not be affected by
subsequent transformations and reactions, and to select the order of synthetic steps
accordingly.
Certain ediate compounds described above form a yet further aspect of the
invention.
The compounds of formula (I) and salts thereof are bromodomain inhibitors, and
thus are believed to have potential utility in the treatment of diseases or conditions for
which a omain inhibitor is ted. Further, compounds of formula (I) and
pharmaceutically acceptable salts thereof (such as the compound of formula (IA) or a
pharmaceutically acceptable salt thereof) may have one or more ADMET (absorption,
distribution, metabolism, excretion and toxicity) property that makes it particularly le.
The present invention thus provides a compound of formula (I) or a
pharmaceutically acceptable salt thereof for use in therapy. In one embodiment there is
provided a compound of formula (IA) or a pharmaceutically acceptable salt thereof for use
in therapy.
The compound of formula (I) or a pharmaceutically acceptable salt thereof can be
used in the treatment of diseases or conditions for which a bromodomain tor is
indicated. The t invention thus provides a compound of formula (I) or a
pharmaceutically acceptable salt thereof for use in the treatment of any diseases or
conditions for which a bromodomain inhibitor is ted. In one embodiment there is
ed a compound of formula (IA) or a pharmaceutically acceptable salt thereof for use
in the treatment of any diseases or ions for which a omain inhibitor is
ted. In another embodiment there is provided a compound of formula (I) (such as a
compound of formula (1A)) or a pharmaceutically acceptable salt thereof for use in the
40 treatment of chronic auto-immune and/or inflammatory ions. In a further
embodiment there is provided a compound of formula (I) (such as a compound of formula
(1A)) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
Also provided is the use of a compound of formula (I) or a pharmaceutically
acceptable salt thereof in the manufacture of a medicament for the treatment of diseases
or conditions for which a bromodomain inhibitor is indicated. For example, in certain
ments there is provided the use of a compound or a pharmaceutically acceptable
salt thereof in the manufacture of a medicament for the treatment of a chronic
autoimmune and/or matory condition, or of cancer, including leukaemia, NUT-
midline carcinoma, multiple myeloma, neuroblastoma, Burkitt's lymphoma, al
cancer, esophageal cancer, ovarian cancer, breast cancer and ctal cancer. In one
embodiment there is provided the use of a compound of formula (IA) or a
pharmaceutically acceptable salt thereof in the manufacture of a medicament for the
treatment of diseases or conditions for which a bromodomain inhibitor is ted.
Also provided is a method of treating diseases or conditions for which a
bromodomain inhibitor is indicated in a subject in need thereof which comprises
administering a therapeutically effective amount of compound of formula (I) or a
pharmaceutically acceptable salt thereof. In one embodiment there is provided a method
of ng diseases or conditions for which a bromodomain inhibitor is indicated in a
subject in need thereof which comprises administering a therapeutically effective amount
of a compound of formula (IA) or a pharmaceutically acceptable salt thereof.
Suitably the subject in need thereof is a mammal, particularly a human.
As used herein, the term "effective amount" means that amount of a drug or
pharmaceutical agent that will elicit the biological or medical response of a tissue, system,
or subject (e.g. a human) that is being sought, for ce, by a researcher or clinician.
Furthermore, the term “therapeutically effective amount” means any amount which, as
compared to a ponding subject who has not received such amount, results in
improved ent, healing, prevention, or amelioration of a disease, disorder, or side
effect, or a se in the rate of advancement of a disease or er. The term also
includes within its scope amounts effective to enhance normal physiological function.
Bromodomain inhibitors are believed to be useful in the treatment of a variety of
diseases or conditions related to systemic or tissue inflammation, inflammatory responses
to infection or hypoxia, cellular activation and proliferation, lipid metabolism, fibrosis and in
the prevention and treatment of viral infections.
Bromodomain inhibitors may be useful in the treatment of a wide variety of chronic
autoimmune and inflammatory conditions such as rheumatoid arthritis, osteoarthritis,
acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory
bowel disease (Crohn’s disease and Ulcerative colitis), asthma, chronic obstructive
airways disease, nitis, ditis, pericarditis, is, eczema, itis
(including atopic dermatitis), alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis,
atherosclerosis, Alzheimer’s disease, depression, Sjögren’s syndrome, denitis,
central retinal vein occlusion, branched retinal vein occlusion, -Gass syndrome (post
40 ct and post-surgical), tis pigmentosa, pars planitis, birdshot
retinochoroidopathy, epiretinal membrane, cystic r edema, parafoveal
telengiectasis, tractional maculopathies, vitreomacular traction syndromes, retinal
detachment, neuroretinitis, idiopathic macular edema, retinitis, dry eye
toconjunctivitis , vernal conjunctivitis, atopic keratoconjunctivitis, s
45 (such as anterior uveitis, pan uveitis, ior uveits, uveitis-associated macula
edema).scleritis, diabetic retinopathy, diabetic macula edema, age-related macula
dystrophy, hepatitis, atitis, primary biliary cirrhosis, sclerosing cholangitis,
Addison’s disease, hypophysitis, ditis, type I diabetes and acute rejection of
transplanted organs.
Bromodomain inhibitors may be useful in the treatment of a wide variety of acute
inflammatory ions such as acute gout, giant cell arteritis, nephritis ing lupus
nephritis, itis with organ involvement such as glomerulonephritis, vasculitis
ing giant cell arteritis, Wegener’s omatosis, teritis nodosa, Behcet’s
disease, Kawasaki disease, Takayasu’s Arteritis, pyoderma gangrenosum, vasculitis with
organ ement and acute rejection of transplanted organs.
Bromodomain inhibitors may be useful in the treatment of diseases or conditions
which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites
or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic
inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock
syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal
failure, ant hepatitis, burns, acute pancreatitis, post-surgical syndromes,
sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria and SIRS
associated with viral infections such as influenza, herpes zoster, herpes simplex and
coronavirus.
Bromodomain inhibitors may be useful in the treatment of conditions associated
with ischaemia-reperfusion injury such as myocardial infarction, cerebro-vascular
ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ
transplantation, ry artery bypass grafting, cardio-pulmonary bypass procedures,
pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism.
Bromodomain inhibitors may be useful in the treatment of disorders of lipid
metabolism via the regulation of APO-A1 such as holesterolemia, atherosclerosis
and Alzheimer’s disease.
Bromodomain inhibitors may be useful in the treatment of fibrotic conditions such
as idiopathic pulmonary is, renal fibrosis, post-operative stricture, keloid scar
formation, scleroderma (including a) and cardiac fibrosis.
Bromodomain inhibitors may be useful in the ent of viral infections such as
herpes virus, human oma virus, adenovirus and us and other DNA viruses.
Bromodomain inhibitors may be useful in the treatment of cancer, including
hematological (such as leukaemia, lymphoma and le myeloma), epithelial including
lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and
neurological tumours.
Bromodomain inhibitors may be useful in the treatment of one or more cancers
selected from brain cancer (gliomas), astomas, Bannayan-Zonana syndrome,
Cowden disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer,
colorectal , Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma,
medulloblastoma, colon cancer, head and neck cancer, kidney cancer, lung cancer, liver
40 cancer, melanoma, squamous cell carcinoma, ovarian , pancreatic , prostate
, sarcoma cancer, osteosarcoma, giant cell tumor of bone, thyroid cancer,
lymphoblastic T-cell leukemia, chronic myelogenous leukemia, chronic lymphocytic
leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous
2012/065918
leukemia, chronic neutrophilic leukemia, acute lymphoblastic T-cell leukemia,
cytoma, immunoblastic large cell leukemia, mantle cell leukemia, multiple
myeloma, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic
leukemia, mixed lineage leukaemia, erythroleukemia, malignant lymphoma, Hodgkins
lymphoma, non-Hodgkins ma, lymphoblastic T-cell lymphoma, t’s ma,
follicular ma, neuroblastoma, bladder cancer, lial cancer, vulval cancer,
cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer,
ry gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer,
buccal , cancer of the mouth, GIST (gastrointestinal stromal tumor) and testicular
cancen
In one embodiment the cancer is a leukaemia, for example a leukaemia selected
from acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous
leukemia, chronic lymphocytic leukemia and mixed e mia (MLL), In another
embodiment the cancer is dline carcinoma. In another embodiment the cancer is
multiple myeloma. In another embodiment the cancer is a lung cancer such as small cell
lung cancer (SCLC). In another ment the cancer is a neuroblastoma. In another
embodiment the cancer is Burkitt's lymphoma. In another embodiment the cancer is
al cancer. In another embodiment the cancer is esophageal cancer. In another
embodiment the cancer is n cancer. In another embodiment the cancer is breast
cancer. In another embodiment the cancer is colarectal cancer.
In one embodiment the disease or condition for which a bromodomain inhibitor is
indicated is selected from diseases ated with systemic inflammatory response
syndrome, such as sepsis, burns, pancreatitis, major , haemorrhage and
ischaemia. In this embodiment the bromodomain inhibitor would be administered at the
point of diagnosis to reduce the incidence of: SIRS, the onset of shock, multi-organ
dysfunction syndrome, which includes the onset of acute lung injury, ARDS, acute renal,
hepatic, cardiac or gastro-intestinal injury and mortality. In another embodiment the
bromodomain inhibitor would be administered prior to surgical or other procedures
associated with a high risk of sepsis, haemorrhage, extensive tissue damage, SIRS or
MODS (multiple organ dysfunction syndrome). In a ular embodiment the disease or
condition for which a bromodomain inhibitor is indicated is sepsis, sepsis syndrome,
septic shock and endotoxaemia. In another embodiment, the bromodomain inhibitor is
indicated for the treatment of acute or chronic atitis. In another embodiment the
bromodomain is indicated for the treatment of burns.
In one embodiment the disease or condition for which a bromodomain inhibitor is
indicated is ed from herpes simplex infections and reactivations, cold sores, herpes
zoster infections and reactivations, chickenpox, shingles, human papilloma virus, human
deficiency virus (HIV), cervical neoplasia, adenovirus infections, including acute
respiratory disease, poxvirus infections such as cowpox and smallpox and African swine
40 fever virus. In one particular embodiment a bromodomain inhibitor is indicated for the
treatment of Human papilloma virus infections of skin or cervical epithelia. In one
embodiment the omain inhibitor is indicated for the treatment of latent HIV
infection.
As used herein the reference to the "treatment" of a particular e or condition
includes the prevention or prophylaxis of such a disease or condition.
The term “diseases or conditions for which a bromodomain inhibitor is indicated”,
is intended to include each of or all of the above es or conditions.
The invention further provides for a method for inhibiting a omain which
comprises contacting the bromodomain with a compound of formula (I) or a
ceutically acceptable salt thereof.
While it is possible that for use in therapy, a compound of formula (I) as well as
pharmaceutically acceptable salts thereof may be administered as the raw chemical, it is
common to present the active ingredient as a pharmaceutical composition.
The present invention therefore provides in a further aspect a pharmaceutical
composition comprising a compound of formula (I) or a pharmaceutically acceptable salt
and one or more pharmaceutically acceptable rs, diluents or excipients. In one
embodiment there is provided a ceutical composition comprising a nd of
formula (IA) or a pharmaceutically acceptable salt and one or more pharmaceutically
acceptable carriers, diluents or excipients. The compounds of formula (I) and
ceutically acceptable salts, are as bed above. The carrier(s), diluent(s) or
excipient(s) must be acceptable in the sense of being compatible with the other
ingredients of the ition and not deleterious to the recipient thereof. In accordance
with another aspect of the ion there is also provided a process for the preparation of
a pharmaceutical composition including admixing a nd of formula (I), or a
pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable
carriers, diluents or excipients. The pharmaceutical composition can be used in the
treatment of any of the conditions described .
Since the compounds of formula (I) are intended for use in pharmaceutical
itions it will be readily understood that they are each preferably provided in
substantially pure form, for example, at least 85% pure, especially at least 98% pure (% in
a weight for weight basis).
Pharmaceutical compositions may be presented in unit dose forms containing a
predetermined amount of active ient per unit dose. Preferred unit dosage
compositions are those containing a daily dose or sub-dose, or an appropriate on
f, of an active ingredient. Such unit doses may therefore be administered more than
once a day. Preferred unit dosage compositions are those containing a daily dose or subdose
(for administration more than once a day), as herein above recited, or an appropriate
fraction thereof, of an active ingredient.
Pharmaceutical compositions may be adapted for administration by any
appropriate route, for example by the oral (including buccal or sublingual), rectal, inhaled,
intranasal, topical (including buccal, sublingual or transdermal), ocular (including topical,
cular, subconjunctival, episcleral, sub-Tenon), vaginal or parenteral (including
40 subcutaneous, intramuscular, intravenous or intradermal) route. Such compositions may
be prepared by any method known in the art of pharmacy, for example by bringing into
ation the active ingredient with the carrier(s) or excipient(s).
In one embodiment the pharmaceutical composition is adapted for parenteral
administration, particularly intravenous administration.
In one embodiment the pharmaceutical composition is adapted for oral
administration.
In one embodiment the pharmaceutical composition is adapted for topical
administration.
Pharmaceutical compositions adapted for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may n anti-oxidants,
buffers, bacteriostats and solutes which render the composition isotonic with the blood of
the intended recipient; and s and non-aqueous sterile suspensions which may
include suspending agents and ning . The compositions may be presented in
ose or multi-dose containers, for example sealed ampoules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example water for injections, immediately prior to use. Extemporaneous
injection solutions and suspensions may be prepared from sterile s, granules and
tablets.
Pharmaceutical compositions adapted for oral administration may be presented as
discrete units such as capsules or tablets; s or granules; solutions or suspensions
in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions
or water-in-oil liquid emulsions.
For instance, for oral stration in the form of a tablet or capsule, the active
drug component can be combined with an oral, non-toxic pharmaceutically acceptable
inert carrier such as ethanol, glycerol, water and the like. s suitable for
incorporating into tablets or capsules may be prepared by reducing the compound to a
suitable fine size (e.g. by micronisation) and mixing with a similarly prepared
pharmaceutical carrier such as an edible carbohydrate, for example, starch or ol.
Flavoring, preservative, dispersing and coloring agent can also be present.
Capsules may be made by preparing a powder mixture, as described above, and
filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc,
ium stearate, calcium stearate or solid polyethylene glycol can be added to the
powder e before the filling operation. A disintegrating or solubilizing agent such as
agar-agar, calcium carbonate or sodium carbonate can also be added to improve the
availability of the medicament when the capsule is ed.
Moreover, when desired or necessary, suitable s, glidants, lubricants,
sweetening agents, flavours, disintegrating agents and ng agents can also be
incorporated into the mixture. le binders include starch, gelatin, natural sugars
such as e or beta-lactose, corn sweeteners, natural and synthetic gums such as
, tragacanth or sodium te, carboxymethylcellulose, polyethylene glycol,
waxes and the like. Lubricants used in these dosage forms include sodium oleate,
sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride
40 and the like. Disintegrators includestarch, methyl cellulose, agar, bentonite, n gum
and the like. Tablets are formulated, for example, by preparing a powder mixture,
ating or slugging, adding a lubricant and disintegrant and pressing into tablets. A
powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent
or base as described above, and optionally, with a binder such as carboxymethylcellulose,
an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a
resorption accelerator such as a quaternary salt and/or an absorption agent such as
ite, kaolin or ium phosphate. The powder mixture can be granulated by
wetting with a binder such as syrup, starch paste, acadia ge or solutions of
cellulosic or polymeric materials and forcing through a screen. As an alternative to
granulating, the powder mixture can be run through the tablet machine and the result is
imperfectly formed slugs broken into granules. The granules can be lubricated to prevent
sticking to the tablet forming dies by means of the on of stearic acid, a te salt,
talc or mineral oil. The lubricated mixture is then compressed into tablets. The
compounds of a (I) and pharmaceutically acceptable salts thereof, can also be
combined with a free flowing inert carrier and compressed into tablets directly t
going through the granulating or ng steps. A clear or opaque protective coating
consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a
polish coating of wax can be provided. Dyestuffs can be added to these coatings to
distinguish different unit dosages.
Oral fluids such as solution, syrups and elixirs can be ed in dosage unit form
so that a given quantity contains a predetermined amount of the compound. Syrups can
be prepared by ving the compound in a suitably flavored aqueous solution, while
elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be
formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and
emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ne sorbitol ethers,
preservatives, flavor additive such as mint oil or natural ners or saccharin or
other artificial sweeteners, and the like can also be added.
Compositions for administration (e.g. oral administration) may be designed to
provide a modified release profile so as to sustain or otherwise control the release of the
therapeutically active agent. A modified release profile of the therapeutically active agent
may be obtained through the design of polymeric matrices incorporating different choices
and properties of biodegradable/bioerodable polymers (e.g. thylene vinyl) acetate
(EVA), superhydrolyzed PVA), hydroxyalkyl cellulose (HPC), methylcellulose (MC),
hydroxypropyl methyl cellulose (HPMC), polycaprolactone, poly(glycolic) acid, actic)
acid, polyanhydride, of polymer molecular weights, polymer crystallinity, copolymer ,
processing conditions, surface finish, geometry, excipient addition and polymeric coatings
that will enhance drug diffusion, erosion, dissolution and osmosis.
Where appropriate, dosage unit itions for oral administration can be
microencapsulated. The composition may be prepared to prolong or n the release
as for e by coating or embedding particulate material in polymers, wax or the like.
The compounds of formula (I) and pharmaceutically acceptable salts thereof, can
also be administered in the form of liposome delivery systems, such as small ellar
40 vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed
from a variety of phospholipids, such as cholesterol, stearylamine or
phosphatidylcholines.
Pharmaceutical compositions adapted for topical stration may be formulated
as ointments, creams, suspensions, emulsions, lotions, powders, solutions, pastes, gels,
foams, sprays, aerosols or oils. Such pharmaceutical compositions may include
conventional additives which include, but are not limited to, preservatives, solvents to
assist drug penetration, co-solvents, ents, propellants, viscosity modifying agents
(gelling agents), surfactants and carriers. In one embodiment there is provided a
pharmaceutical composition d for topical administration which comprises between
0.01 — 10%, or between 0.01 — 1% of the compound of formula (I), or a pharmaceutically
acceptable salt thereof, by weight of the composition.
For treatments of the eye or other external tissues, for e mouth and skin,
the compositions are ably applied as a topical ointment, cream, gel, spray or foam.
When formulated in an nt, the active ingredient may be employed with either a
paraffinic or a water-miscible ointment base. atively, the active ingredient may be
formulated in a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical compositions adapted for l strations to the eye
include eye drops wherein the active ingredient is dissolved or suspended in a suitable
carrier, especially an aqueous solvent. Compositions to be stered to the eye will
have ophthalmically compatible pH and osmolality. One or more ophthalmically
acceptable pH adjusting agents and/or buffering agents can be included in a composition
of the invention, including acids such as acetic, boric, citric, lactic, phosphoric and
hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate,
sodium citrate, sodium acetate, and sodium lactate; and buffers such as citrate/dextrose,
sodium bicarbonate and ammonium chloride. Such acids, bases, and buffers can be
included in an amount required to maintain pH of the composition in an ophthalmically
acceptable range. One or more ophthalmically acceptable salts can be included in the
composition in an amount sufficient to bring osmolality of the composition into an
lmically acceptable range. Such salts include those having , potassium or
ammonium cations and chloride, e, ascorbate, borate, phosphate, bicarbonate,
sulfate, thiosulfate or ite anions.
The ocular delivery device may be designed for the controlled release of one or
more therapeutic agents with multiple defined release rates and sustained dose kinetics
and permeability.
Pharmaceutical compositions for ocular delivery also include in situ gellable
aqueous composition. Such a composition comprises a g agent in a concentration
effective to promote g upon contact with the eye or with lacrimal fluid. Suitable
gelling agents include but are not d to thermosetting polymers. The term "in situ
gellable" as used herein is includes not only liquids of low viscosity that form gels upon
contact with the eye or with lacrimal fluid, but also includes more viscous liquids such as
semi-fluid and thixotropic gels that exhibit substantially increased viscosity or gel ess
upon administration to the eye. See, for example, Ludwig (2005) Adv. Drug Deliv. Rev.
40 3;57:1595—639, herein incorporated by reference for es of its teachings of
examples of polymers for use in ocular drug ry.
Dosage forms for nasal or inhaled administration may conveniently be formulated
as aerosols, solutions, suspensions, gels or dry powders.
For compositions suitable and/or adapted for d administration, it is preferred
that the compound of formula (I) or a pharmaceutically acceptable salt thereof, is in a
particle-size-reduced form e.g. obtained by micronisation. The preferable particle size of
the size-reduced (e.g. micronised) compound or salt is defined by a D50 value of about
0.5 to about 10 microns (for example as measured using laser diffraction).
Aerosol ations, e.g. for inhaled administration, can comprise a solution or
fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-
aqueous solvent. Aerosol formulations can be presented in single or multidose quantities
in sterile form in a sealed container, which can take the form of a cartridge or refill for use
with an atomising device or inhaler. atively the sealed container may be a unitary
dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a
metering valve (metered dose inhaler) which is intended for disposal once the contents of
the container have been exhausted.
Where the dosage form comprises an aerosol dispenser, it preferably ns a
suitable propellant under pressure such as compressed air, carbon dioxide or an organic
propellant such as a hydrofluorocarbon (HFC). Suitable HFC propellants include
1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage
forms can also take the form of a pump-atomiser. The pressurised aerosol may contain a
solution or a suspension of the active compound. This may require the incorporation of
onal excipients e.g. co-solvents and/or surfactants to improve the sion
characteristics and homogeneity of suspension formulations. Solution formulations may
also require the addition of co-solvents such as ethanol.
For pharmaceutical compositions suitable and/or adapted for inhaled
administration, the pharmaceutical composition may be a dry powder inhalable
ition. Such a composition can se a powder base such as lactose, glucose,
ose, mannitol or starch, the compound of formula (I) or a pharmaceutically
acceptable salt thereof (preferably in le-size-reduced form, e.g. in micronised form),
and optionally a performance modifier such as L-leucine or r amino acid and/or
metal salt of stearic acid such as magnesium or calcium stearate. Preferably, the dry
powder inhalable ition comprises a dry powder blend of e e.g. lactose
monohydrate and the compound of formula (I) or salt thereof. Such compositions can be
administered to the t using a suitable device such as the DISKUS® device,
marketed by GlaxoSmithKline which is for example described in GB 2242134 A.
The compounds of formula (I) and pharmaceutically acceptable salts thereof may
be formulated as a fluid formulation for delivery from a fluid ser, for example a fluid
dispenser having a dispensing nozzle or dispensing orifice through which a d dose
of the fluid formulation is dispensed upon the application of a user-applied force to a pump
mechanism of the fluid dispenser. Such fluid sers are generally provided with a
reservoir of multiple d doses of the fluid formulation, the doses being dispensable
40 upon sequential pump actuations. The dispensing nozzle or orifice may be configured for
insertion into the nostrils of the user for spray dispensing of the fluid formulation into the
nasal cavity. A fluid ser of the aforementioned type is described and illustrated in
WO-A—2005/044354.
A therapeutically effective amount of a compound of formula (I) or a
pharmaceutically acceptable salt f, will depend upon a number of factors ing,
for e, the age and weight of the subject, the precise condition requiring treatment
and its severity, the nature of the formulation, and the route of administration, and will
ultimately be at the discretion of the attendant physician or veterinarian. In the
pharmaceutical ition, each dosage unit for oral or parenteral administration
preferably ns from 0.01 to 3000 mg, more preferably 0.5 to 1000 mg, of a
compound of formula (I) or a pharmaceutically acceptable salt f, calculated as the
free base. Each dosage unit for nasal or inhaled administration preferably contains from
0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of the formula (I) or a
ceutically acceptable salt thereof, calculated as the free base.
The pharmaceutically acceptable compounds of formula (I) and ceutically
acceptable salts f, can be stered in a daily dose (for an adult patient) of, for
example, an oral or parenteral dose of 0.01 mg to 3000 mg per day, 0.5 to 1000 mg per
day or 100 mg to 2500mg per day, or a nasal or inhaled dose of 0.001 to 50 mg per day
or 0.01 to 5 mg per day, of the compound of the formula (I) or a pharmaceutically
acceptable salt thereof, calculated as the free base. This amount may be given in a
single dose per day or more usually in a number (such as two, three, four, five or six) of
sub-doses per day such that the total daily dose is the same. An ive amount of a
salt thereof, may be determined as a proportion of the effective amount of the compound
of formula (I) per se.
The compounds of a (I) and pharmaceutically acceptable salts thereof, and
may be employed alone or in combination with other therapeutic agents. Combination
therapies according to the present invention thus comprise the administration of at least
one compound of formula (I) or a pharmaceutically acceptable salt thereof, and the use of
at least one other therapeutically active agent. Preferably, combination therapies
according to the present invention comprise the administration of at least one compound
of formula (I) or a pharmaceutically acceptable salt thereof, and at least one other
therapeutically active agent. The compound(s) of formula (I) and pharmaceutically
acceptable salts thereof, and the other therapeutically active agent(s) may be
administered together in a single pharmaceutical composition or separately and, when
administered separately this may occur simultaneously or sequentially in any order. The
amounts of the compound(s) of formula (I) and pharmaceutically acceptable salts thereof,
and the other eutically active agent(s) and the relative timings of administration will
be ed in order to achieve the desired combined therapeutic effect. Thus in a further
aspect, there is provided a combination pharmaceutical product sing a nd
of formula (I) or a pharmaceutically acceptable salt f, and at least one other
therapeutically active agent.
Thus in one aspect, the compound of formula (I) or a pharmaceutically acceptable
40 salt thereof, and pharmaceutical compositions comprising a compound of formula (I) or a
pharmaceutically acceptable salt thereof, according to the invention may be used in
ation with or include one or more other therapeutic agents, for example selected
from antibiotics, anti-virals, glucocorticosteroids, muscarinic antagonists beta-2 agonists
2012/065918
and Vitamin D3 analogues. In a r embodiment a compound of formula (I) or a
pharmaceutically acceptable salt thereof may be used in ation with a further
therapeutic agent which is suitable for the treatment of cancer. Examples of such further
therapeutic agents are desfibed in Cancer Principles and Practice of Oncology by V.T.
Devita and S. Hellman (editors), 6th edition (2001), cott Williams & Wilkins
Publishers. A person of ordinary skill in the art would be able to n which
combinations of agents would be useful based on the particular characteristics of the
drugs and the cancer involved. Further therapeutic agents to be used in combination with
the compound of formula (I) or a pharmaceutically acceptable salt thereof include, but are
not limited to, anti-microtubule agents (such as diterpenoids and vinca alkaloids); platinum
coordination complexes; alkylating agents (such as nitrogen mustards,
oxazaphosphorines, alkylsulfonates, nitrosoureas, and triazenes); antibiotic agents (such
as anthracyclins, actinomycins and bleomycins); topoisomerase II inhibitors (such as
epipodophyllotoxins); antimetabolites (such as purine and pyrimidine analogues and anti-
folate compounds); topoisomerase I inhibitors (such as camptothecins; hormones and
al analogues); signal transduction pathway inhibitors (such as tyropsine receptor
tors); non-receptor tyrosine kinase enesis inhibitors; immunotherapeutic
agents; proapoptotic agents; epigenetic or transcriptional modulators (such as histone
ylase inhibitors) and cell cycle signaling inhibitors.
It will be appreciated that when the compound of formula (I) or a ceutically
acceptable salt thereof, is stered in combination with other eutic agents
normally administered by the inhaled, intravenous, oral or intranasal route, that the
resultant pharmaceutical composition may be stered by the same routes.
Alternatively the individual components of the composition may be administered by
different routes.
One embodiment of the invention encompasses combinations comprising one or
two other therapeutic agents.
It will be clear to a person d in the art that, where appropriate, the other
therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or
amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl
esters, or as solvates, for example hydrates, to optimise the ty and/or stability and/or
physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear
also that, where appropriate, the therapeutic ingredients may be used in optically pure
form.
The combinations referred to above may conveniently be presented for use in the
form of a pharmaceutical composition and thus ceutical compositions comprising a
combination as defined above together with a pharmaceutically acceptable diluent or
carrier represent a further aspect of the ion.
The compounds of formula (I) and pharmaceutically acceptable salts thereof, may
40 be prepared by the methods bed below or by similar methods. Thus the following
Intermediates and Examples serve to rate the preparation of the compounds of
formula (I) and pharmaceutically able salts thereof, and are not to be considered as
limiting the scope of the invention in any way.
WO 24104 2012/065918
General Experimental details
All temperatures referred to are in OC.
The names of the following compounds have been obtained using the compound
naming programme “ACD Name Pro 6.02” or Chem Draw Ultra 12.0.
Abbreviations
1,2—DCE 1,2—dichloroethane
AcOH acetic acid
CHCI3 chloroform
D6—DMSO deuterated dimethylsulfoxide
DCM dichloromethane
DIPEA diisopropylamine
DMSO dimethylsulfoxide
DPPA diphenylphosphoryl azide
Et3N triethylamine
EtOAc ethyl acetate
h hour(s)
HATU O—(7-Azabenzotriazoly|)-N,N,N’,N’-tetramethyluronium
hexafluorophosphate
HCI hloric acid
i-PrOac pylacetate
i-PrZO diisopropyl ether
LCMS liquid chromatography—mass spectrometry
LiOH lithium hydroxide
M molar (concentration)
MeCN acetonitrile
MeOH methanol
min minute(s)
N normal (concentration)
N32003 sodium carbonate
NaZSO4 sodium sulphate
Pd/C ium on carbon
Rt retention time
TBME tertiary butyl methyl ether
TFA trifluoroacetic acid
THF tetrahydrofuran
UPLC Ultra performance liquid chromatograpy
40 LCMS methodology
Method Formate
LC conditions
The UPLC analysis was conducted on an Acquity UPLC BEH C18 column (50mm x
2.1mm, i.d. 1.7um packing diameter) at 400C.
The solvents employed were:
A = 0.1% v/v solution of formic acid in water
B = 0.1% v/v solution of formic acid in acetonitrile
The radient emolo ed was:
Flowrate mI/min
-———
———-—
———-—
The UV detection was a summed signal from ngth of 210nm to 350nm.
MS conditions
MS : Waters ZQ
tion mode : Alternate-scan positive and negative electrospray
Scan range : 100 to 1000 AMU
Scan time : 0.27sec
Inter scan delay : 0.10sec
NMR
Spectra were run on a 400mHz NMR e at either 302 K or for VT spectra at 392-
393 K.
Intermediate 1
7-(3,5-dimethylisoxazolyl)methoxy-N-(1-methoxypropanyl)nitroquinolin
amine
To a solution of 4-(4-chloro-6—methoxy—3-nitroquinolinyl)-3,5-dimethylisoxazole
ester Organics) (20 g, 59.9 mmol) in 1,4-dioxane (200 ml) was added 1-
methoxypropanamine (31.6 ml, 300 mmol) and the reaction mixture heated at 70 °C for
1.5 h. The solvent was removed under reduced pressure and the resulting solid
partitioned between ethyl acetate (3 x 750 ml) and water (750 ml). The c layers
were combined, dried (hydrophobic frit) and evaporated under reduced pressure to give 7-
(3,5-dimethylisoxazolyl)-6—methoxy-N-(1-methoxypropanyl)—3-nitroquinolinamine
(25.8 g), which was used without further purification in the subsequent step.
NMR SO): 8H 9.03(s, 1H), 8.63(d, 1H), 7.83(s, 1H), 7.81(s, 1H), 4.39(m, 1H),
3.97(s, 3H), 3.54(m, 2H), 3.27(s, 3H), 2.34(s, 3H), 2.15(s, 3H), 1.41(d, 3H).
LCMS (formate): Rt = 0.97 min, MH+ 387.
Intermediate 2
7-(3,5-dimethylisoxazolyl)methoxy-N4-(1-methoxypropanyl)quinoline-3,4-
diamine
7-(3,5-Dimethylisoxazolyl)methoxy-N-(1-methoxypropanyl)—3-nitroquinolin-
4-amine (for a ation see Intermediate 1)(25.8 g, 66.8 mmol) was dissolved in a
mixture of ethyl acetate (1000 ml) and DMSO (50 ml) and the solution was hydrogenated
using a flow-hydrogenation apparatus (H-cubeT'V') (settings: 20 °C, 1 bar, n flow
rate) and a 10 % Pd/C CatCart 70 catalyst cartridge. The catalyst cartridge was changed
whenever it became blocked. The reaction mixture was evaporated under reduced
pressure and ioned between ethyl acetate (750 ml) and water (3 x 750 ml). The
aqueous layers were combined and extracted with ethyl e (750 ml). The organic
layers were were combined, dried (hydrophobic frit) and evaporated under reduced
pressure. The residue was dissolved in DCM and applied to a silica cartridge (100 g).
The cartridge was eluted with a 2M a in methanol / DCM nt (0-4 %). The
appropriate fractions were ed and evaporated under reduced pressure to give 7-
(3,5-dimethylisoxazolyl)methoxy-N4-(1-methoxypropanyl)quinoline-3,4-diamine
and recovered -dimethylisoxazolyl)methoxy-N-(1-methoxypropanyl)—3—
nitroquinolinamine (6.5 g)
The recovered starting material was dissolved in ethyl acetate (250 ml) and the
solution was hydrogenated using using a flow-hydrogenation apparatus (H-cubeT'V')
(settings: 20 °C, 1 bar, 1ml/min flow rate) and 10 % Pd/C CatCart 70 catalyst cartridge.
The reaction mixture was evaporated under reduced pressure and the residue was
ved in DCM and applied to a silica cartridge (100 g). The cartridge was eluted with
a 2M ammonia in methanol / DCM gradient (0-4 %). The riate fractions were
ed and evaporated under reduced pressure to give 7-(3,5-dimethylisoxazolyl)—6-
methoxy-N4-(1-methoxypropanyl)quinoline-3,4-diamine
The batches of product were combined to give 7-(3,5-dimethylisoxazolyl)—6-
methoxy-N4-(1-methoxypropanyl)quinoline-3,4-diamine (15.6 g, 43.8 mmol, 65.6 %
yield) as a sticky dark brown gum.
NMR (De-DMSO): 8H 8.29(s, 1H), 7.55(s, 1H), 7.45(s, 1H), 5.13(s, 2H), 4.48(d,
1H), 3.88(s, 3H), 3.54(m, 1H), 3.35(m, 2H), 3.29(s, 3H), 2.30(s, 3H), , 3H), 1.18(d,
3H). LCMS (formate): Rt 0.73 min, MH+ 357
Intermediate 3
N-(7-(3,5-dimethylisoxazolyl)methoxy((1-methoxypropan
yl)amino)quinolinyl)tetrahydro-2H-pyrancarboxamide
WO 24104
A solution of 7-(3,5-dimethylisoxazolyl)methoxy-N4-(1-methoxypropan
yl)quinoline-3,4-diamine (for a preparation see Intermediate 2) (9.1g) in DCM (300ml) was
d with pyridine (30ml) and tetrahydro-2H-pyrancarbonyl chloride (5.0ml) and the
on stirred under nitrogen at ambient temperature for 3.5h and then left standing
overnight (ambient temperature, under nitrogen). The volatiles were evaporated in vacuo
and the residue partitioned n DCM and water. The organic phase was washed
with water x2 and the combined aqueous extracted with DCM. The combined c
phases were washed with brine, dried (hydrophobic frit) and reduced to s in vacuo.
The combined s including the brine wash (~pH4) was basified with solid sodium
hydrogen carbonate and the aqueous extracted with DCM x2. The organic fractions were
dried (hydrophobic frit), combined with the previous material and reduced to dryness in
vacuo to give a brown foam. This foam was further dried in vacuo, triturated with diethyl
ether, the suspension chilled (ice/water bath) and the solid isolated by filtration. The solid
was washed with a little diethyl ether and air-dried to give N-(7-(3,5-dimethylisoxazolyl)-
6-methoxy—4-((1-methoxypropanyl)amino)quinolinyl)tetrahydro-2H-pyran
carboxamide as a beige solid (11.95g, 100%).
NMR (De-DMSO): 8H 9.49(s, 1H), 8.38(s, 1H), 7.70(s, 1H), 7.63(s, 1H), 5.33(d,
1H), 3.96-3.90(m, 6H), 3.43-3.28(m partially ed by water, 7H), 2.69(m, 1H), 2.32(s,
3H), 2.12(s, 3H), 1.81-1.67(m, 4H), 1.19(d, 3H). LCMS te): Rt 0.69 mins, MH+ 469.
Example 1
4-(8-methoxy(1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-
c]quinolinyl)-3,5-dimethylisoxazole
A suspension of N-(7-(3,5-dimethylisoxazolyl)methoxy((1-methoxypropan-
2-y|)amino)quinoliny|)tetrahydro-2H-pyrancarboxamide (for a preparation see
Intermediate 3) (29.4 g, 62.7 mmol) in acetic acid (250 mi, 62.7 mmol) was heated at 120
°C for 2 h. 3 A molecular sieves (20 g) were added and heating continued for 3.5 h.
Further 3 A molecular sieves (20 g, oven dried) were added and heating was continued
overnight. Further 3 A molecular sieves (20 g, oven dried) were added and heating
continued for a further 24 h.
The reaction mixture was allowed to cool to room temperature, and the solid
removed by filtration. The residue and filtrate were combined and evaporated under
reduced re. Water (3 I) was added, and the resultant slurry was neutralised by the
slow addition of solid sodium hydrogen carbonate. The aqueous slurry was extracted with
DCM (3 x 1 l), and the organic phases were combined, dried (hydrophobic frit) and
evaporated under reduced pressure to give a brown gum.
The gum was dissolved with warming and tion in a l quantity of
DCM. The solution was applied to a silica column (750 g) which had been tted with
DCM. The column was eluted with a gradient of [2 M ammonia in methanol, ol
(3:1)] / DCM (0-~8 %). The product fractions were combined and d to dryness
under reduced pressure to give a cream foam /glass 7 g).
The mixed product fractions were combined and reduced to s under
reduced pressure to give a deep yellow oil. This oil was dissolved in diethyl ether and the
volatiles evaporated in vacuo to give a yellow solid. The solid was triturated with diethyl
ether, the solid isolated by filtration and washed with diethyl ether (x 2) to give 4-(8—
methoxy(1-methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-imidazo[4,5—
c]quinolinyl)—3,5-dimethylisoxazole.
The cream foam / glass was triturated with diethyl ether/ ethyl acetate, the mixture
reduced to dryness under reduced pressure and the trituration was repeated with diethyl
ether. The previous product fraction was added to the suspension and the mixture aged
overnight. The solid was isolated by filtration and washed with diethyl ether to give 4-(8—
methoxy(1-methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-imidazo[4,5—
c]quinolinyl)—3,5—dimethylisoxazole as a cream solid. The solid was dried in vacuo and
retriturated with l ether with stirring over ~30 min. The solid was isolated by filtration
and washed with diethyl ether. The solid was dried in vacuo to give ethoxy(1-
methoxypropanyl)(tetrahydro-2H-pyranyl)—1H-imidazo[4,5-c]quinolinyl)-3,5-
dimethylisoxazole as a white solid (11.73 g).
VT NMR (De-DMSO): 8H 9.04(s, 1H), 7.99(s, 1H), 7.74(s, 1H), 5.45(m, 1H),
4.14(m, 1H), 4.06-4.01(m, 6H), 3.62(m, 2H), 3.47(m, 1H), 3.28(s, 3H), 2.35(s, 3H), ,
3H), 2.09(m, 2H), 1.92(m, 2H), 1.83(d, 3H). LCMS(formate): Rt 0.76min, MH+ 451.
Example 1 — alternative ation
4-(8-methoxy(1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-
c]quinolinyl)-3,5-dimethylisoxazole
A e of N-(7-(3,5-dimethylisoxazolyl)methoxy((1-methoxypropan
yl)amino)quinolinyl)tetrahydro-2H-pyrancarboxamide (for a preparation see
Intermediate 3) (11.95 g, 25.5 mmol) and p-toluenesulfonic acid (1.2 g, 25.5 mmol) in
toluene (250 ml) was heated under nitrogen at reflux using a Dean-Stark tus for 3
days. Further p-toluenesulfonic acid (0.2 g, 4.3 mmol) was added and heating continued
overnight. Water (750 ml) was added, and the e basified to pH 8 using saturated
40 aqueous sodium hydrogen carbonate solution. The aqueous was extracted with ethyl
acetate (3 x 750 ml), the organic layers combined, dried (hydrophobic frit) and evaporated
under reduced pressure. The residual solid was triturated in ether (~200 ml), sonicated
briefly. The majority of the solid appeared to be a fine powder. The fine powder
suspended in the ether was decanted, the solid isolated by filtration, and dried in a
vacuum oven to give crude 4-(8-methoxy(1-methoxypropanyl)(tetrahydro-2H-
pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole (6.3 g). This material
was triturated in ether (~100 ml), sonicated briefly, and stood overnight at room
temperature. The solid was isolated by filtration and dried in a vacuum oven 4-(8-
methoxy(1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1 H-imidazo[4,5—
c]quinolinyl)—3,5—dimethylisoxazole (4.9 g, 10.88 mmol, 42.6 % yield). LCMS(formate):
Rt 0.75 min, MH+ 451.
The clumped solid left over from the ing was triturated in ether (100 ml),
sonicated for 15 min, and stood at room temperature for 3 days. The solid was isolated by
filtration and dried in a vacuum oven to give 4-(8-methoxy(1-methoxypropanyl)-2—
(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)—3,5-dimethylisoxazole (3.6 g,
7.99 mmol, 31.3 % yield). LCMS(formate): Rt 0.76min, MH+ 451.
Example 2
4-(8-methoxy((R)methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-
imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole
o/Z{QO
Chiral resolution of 4-(8-methoxy(1-methoxypropanyl)(tetrahydro-2H-
4-yl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole was carried out using
the following ions:
: Chiralpak AD-H (250 x 30mm, 5micron) [ADH10029—01]
te: 45 ml/min
Detection: UV DAD (300nm (bandwidth 180nm, reference 550nm (bandwidth 100nm)).
Mobile Phase A: n-Hexane (10ml of isopropylamine per Winchester )
Mobile Phase B: Ethanol (10ml of isopropylamine per ster (2.5L))
lsocratic system — 85:15 mobile phase A:B
Run time — ca. 35min
4-(8-methoxy(1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1 H-
o[4,5—c]quinolinyl)—3,5-dimethylisoxazole (500mg) was suspended in ethanol and
ethylene glycol (10 ml:5 ml) and then sonicated and heated to aid solution.
lsopropylamine (1 ml) was then added. This working solution was warmed on a hotplate
(60 OC) whilst purification was ongoing to keep in solution. Injections (1.5 ml) were made
using autosampler. Fractions collected on time basis using funnel bed fraction collector
between 28min and 35min. The combined fraction solutions were ated to dryness
using a rotary evaporator (30 OC bath temp) and the residue transferred to a tared 20ml
2012/065918
glass vial using ethanol (ca 12 ml). The ethanol was evaporated under a stream of
nitrogen gas (room temp).
4-(8-methoxy—1-((R)—1-methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-
imidazo[4,5—c]quinolinyl)—3,5-dimethylisoxazole (1.16g) ed using the above
s was triturated with diethyl ether (~3ml) over ~4h at ambient temperature. The
solid was isolated by filtration, washed with diethyl ether and dried in vacuo to give 4-(8-
methoxy((R)methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-
c]quinolinyl)—3,5—dimethylisoxazole as a cream solid (0.96g).
VT NMR (De-DMSO): 8H 9.03(s, 1H), 7.98(s, 1H), 7.74(s, 1H), 5.43(m, 1H),
4.13(m, 1H), 4.04-4.00(m, 6H), 3.61(m, 2H), 3.46(m, 1H), , 3H), , 3H), 2.16(s,
3H), 2.08(m, 2H), 1.92(m, 2H), 1.82(d, 3H). LCMS (formate): Rt 0.76min, MH+ 451.
Example 3
4-(8-methoxy((S)methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-
o[4,5-c]quinolinyl)-3,5-dimethylisoxazole
| 29U
Chiral resolution of 4-(8-methoxy—1-(1-methoxypropanyl)(tetrahydro-2H-
pyranyl)—1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole was carried out using
the following conditions:
Column: Chiralpak AD-H (250 x 30mm, 5micron) [ADH10029—01]
Flowrate: 45 ml/min
Detection: UV DAD (300nm (bandwidth 180nm, reference 550nm (bandwidth 100nm)).
Mobile Phase A: Heptane
Mobile Phase B: Ethanol
lsocratic system — 85:15 mobile phase A:B
Run time — ca. 35min
4-(8-methoxy—1-(1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-
imidazo[4,5—c]quinolinyl)—3,5-dimethylisoxazole (85mg) was dissolved in ethanol (ca. 4
ml) with heating and sonication. Injections (400 pl) were then made via plastic syringe.
The fractions n 24min and 26.5min were collected and the combined fraction
solutions were evaporated to dryness using a rotary evaporator (30 OC bath temp). The
residue was transferred to a tared glass vial using ethanol (ca 12 ml). The solvent was
then removed by evaporation under a stream of nitrogen gas (room temp) to give 4-(8-
methoxy((S)methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-imidazo[4,5—
c]quinolinyl)—3,5—dimethylisoxazole (38 mg).
VT NMR SO): 8H 9.00(s, 1H), 7.95(s, 1H), 7.72(s, 1H), 5.41(m, 1H),
4.10(m, 1H), .97(m, 6H), 3.59(m, 2H), 3.45(m, 1H), 3.26(s, 3H), 2.32(s, 3H), 2.13(s,
3H), 2.07(m, 2H), 1.90(m, 2H), 1.80(d, 3H). LCMS(formate): Rt 0.73min, MH+ 451.
Example 4
Preparation of a crystalline form of ethoxy((R)methoxypropanyl)
(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole
(anhydrous form 1)
4-(8-methoxy—1-((R)—1-methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-
imidazo[4,5-c]quinolinyl)—3,5-dimethylisoxazole (for a preparation see Example 2 or
on scheme 1, ) was dissolved in isopropyl acetate (95 mL) at reflux and then
allowed to cool to 20 0C over 1hr. Cyclohexane (190 mL) was then added over 1hr and
the resultant slurry was aged for 1 hr. The slurry was then filtered and washed with 2:1
exane : isopropylacetate (30 mL) and then cyclohexane (30 mL) before being
pulled dry. The cake was then oven dried overnight at 40 °C under . An XRPD
was recorded on this material (see Example 9).
Example 5
Preparation of a crystalline form of 4-(8-methoxy((R)methoxypropanyl)
(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole
(anhydrous form 2)
A pre—mixed solution of isopropyl acetate (211 mL) and exane (422 mL)
was added to 4-(8—methoxy—1-((R)—1-methoxypropany|)(tetrahydro-2H-pyranyl)—
1H-imidazo[4,5-c]quin0|inyl)-3,5-dimethy|isoxazole (for a preparation see e 2 or
reaction scheme 1, 42.19g, 94 mmol). The resulting suspension was stirred for 24 hours,
filtered, the resulting solid washed (1x cyclohexane : isopropyl acetate (2:1, 180ml), 1x
cyclohexane (180ml), 1x TBME (180 ml)), pulled to dryness and dried in vacuo at 40 0C to
constant weight giving an almost white solid (90% yield). An XRPD was recorded on this
material (see Example 9).
Preparation of a crystalline form of 4-(8-methoxy((R)methoxypropanyl)
(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole
(hydrate)
A pre—mixed solution of ethanol (2.000 mL) and water (8.00 mL) was added to 4-
hoxy((R)—1-methoxypropanyl)(tetrahydro-2H-pyrany|)-1H-imidazo[4,5-
c]quinolinyl)—3,5—dimethylisoxazole (for a preparation see Example 2 or reaction
scheme 1, 1.00 g, 2.220 mmol) and the resulting suspension stirred overnight. The
suspension was filtered, washed (2x water, 2x TBME ), pulled to dryness under vacuum
and dried in vacuo at 40 0C to give a white powder. An XRPD was recorded on this
material (see Example 9).
Example 7
Preparation of a crystalline form of 4-(8-methoxy((R)methoxypropanyl)
(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole
40 (anhydrous form 3)
4-(8-methoxy—1-((R)—1-methoxypropanyl)—2-(tetrahydro-2H-pyranyl)—1 H-
imidazo[4,5-c]quinolinyl)—3,5-dimethylisoxazole e (for a preparation see Example
6, 860 mg, 1.835 mmol) was heated at 135 0C at 9 mbar overnight. An XRPD was
recorded on this material (see Example 9).
Preparation of 4-(8-methoxy((R)methoxypropanyl)(tetrahydro-2H-pyran
yl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole hydrochloride
(hydrochloride)
In a first reactor a solution of 7-(3,5-dimethylisoxazolyl)methoxy(N-((R)—1-
methoxypropanyl)tetrahydro-2H-pyrancarboxamido)quinoline—3-carboxylic acid (for a
preparation see Scheme 1, 23.3 kg) in DCM (113 kg) and DIPEA (3.8 kg) was combined
with acetonitrile (61.6 kg) and di-iso-propylamine (12.8 kg) the e was cooled to
between -10 and -3°C. Diphenylphosphoryl azide (19.0 kg) was added ining the
temperature between -10 and -3 °C and the reaction stirred at this temperature. Further
diphenylphosphoryl azide (2.4 kg) was added maintaining the temperature between -10
and -3 °C and the reaction stirred at this ature to form a first solution.
In a second r dimethyl formamide (144 kg) and water (72 kg) were heated to
90-100 °C. The first on was added maintaining the temperature between 85-100 °C,
reactor 1 was rinsed with acetonitrile (7 kg) and the rinse added to the second reactor
maintaining the temperature between 85-100 °C. The mixture was stirred at this
temperature and then cooled to 20-30 °C. The pH was adjusted to pH=10 with 30%wt
aqueous sodium hydroxide solution (10.4 kg) maintaining the temperature between 20-
30 °C. romethane (315 kg) and water (351 kg) were charged, the layers were
separated and the s layer extracted with dichloromethane (315 kg). The ed
organic layers were washed with water (234kg). Water (234 kg) was charged to the
organic layer, the mixture stirred, sodium chloride (80 kg) added and the layers separated.
The organic layer was concentrated under reduced pressure below 30 °C, methanol (201
kg) was d and the solution concentrated under reduced pressure below 50 °C.
r methanol (199 kg) and 4M hydrochloric acid in methanol (68.5 kg) were charged
maintaining the temperature 20-30 °C and the reaction was stirred at this temperature.
The mixture was concentrated under reduced pressure below 50 °C and acetonitrile (104
kg) charged. The mixture was concentrated under reduced pressure below 50 °C and
further acetonitrile (97 kg) charged. The mixture was concentrated under reduced
pressure below 50 °C and further acetonitrile (116 kg) charged. The mixture was
evaporated under reduced pressure below 50 °C and further acetonitrile (103.0 kg) was
charged. The mixture was cooled to between 0 °C and stirred at this ature. The
slurry was centrifuged in two portions, each portion was washed with acetonitrile (9 kg) to
give the title compound (33.40 kg, 99.3% purity) as a wet cake.
Example 9
X-ray powder diffraction (XRPD) studies on crystalline forms of ethoxy((R)-
1-methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-
3,5-dimethylisoxazole as a free base and as a hydrochloride salt
40 The data were ed on a PANalytical X’Pert Pro powder diffractometer, model
PW3040/60 using an X’Celerator detector. The acquisition conditions were: radiation: Cu
Kq, generator n: 40 kV, generator current: 45 mA, start angle: 20° 20, end angle:
400° 20, step size: 0.0167° 20, time per step: 31.75 seconds. The sample was prepared
by mounting a few milligrams of sample on a silicon wafer (zero background) plate,
resulting in a thin layer of powder.
Peak ons were measured using ore software. The margin of error is
approximately i 0.1° 26 for each of the peak assignments. Peak intensities may vary from
sample to sample due to preferred orientation.
Table 1 shows characteristic XRPD peak positions and d-spacings for crystalline
form of the compound 4-(8—methoxy((R)methoxypropanyl)(tetrahydro-2H-
pyrany|)-1H-imidazo[4,5-c]quinolinyl)—3,5-dimethylisoxazole as a free base and as a
hydrochloride salt.
Table 1
Free base Free base Free base Free base hydrochloride
anhydrous ous form 2 anhydrous form 3 Hydrate
form 1
__6—. 9-4
----—--a_--
---_-_--_
-—-_
---_-_--_
--_-_-
---_-_-_--
Biological Test Methods
The compounds of formula (I) may be tested in one or more of the following assays.
Time ed Fluorescence Resonance Energy er (TR-FRET) assay
The binding of the compounds of formula (I) to Bromodomains BRD2, BRD3 and
BRD4 was assessed using a time resolved fluorescent resonance energy transfer binding
assay, that measures the binding of an acetylated histone peptide to the bromodomain
protein.
The bromodomain protein, histone peptide and a variable concentration of test
compound are incubated together to reach thermodynamic equilibrium. The assay is
configured such that in the absence of test compound the bromodomain and peptide are
significantly bound (~30%) and in the presence of a sufficient concentration of a potent
inhibitor this interaction is disrupted leading to a measurable drop in fluorescent
resonance energy transfer.
Histone e:
H-Ser-Gly-Arg-Gly-Lys(Ac)—Gly-Gly-Lys(Ac)—Gly-Leu-Gly-Lys(Ac)-Gly-Gly-Ala-Lys(Ac)—
Arg-His-Gly-Ser-Gly-Ser-Lys(Biotin)—OH. 3TFA
The protected peptide was assembled on a solid-phase synthesiser using
preloaded Wang resin and utilising standard Fmoc synthesis protocols. The C-terminal
lysine was protected by a hyper acid-labile group allowing for its selective removal at the
end of the assembly and attachment of the . The crude peptide was obtained after
cleavage from the resin with a mixture of trifluoroacetic acid (TFA), triisopropylsilane and
water (95:2.5:2.5) for 3h at room temperature and was then purified using a C18 e-
phase column utilising a 0.1%TFA—buffered water/acetonitrile gradient. The resulting
fractions were analysed and fractions which were >95% pure by analytical HPLC and
giving the correct mw (by MALDiTOF mass spectroscopy) were pooled and freeze dried.
The final al was analysed by HPLC to m .
Protein production: inant Human Bromodomains (BRD2 (1-473), BRD3 (1-435)
and BRD4 (1-477)) were expressed in Eco/i cells (in pET15b vector) with a six-His tag at
the N-terminal. The His-tagged Bromodomain was extracted from Eco/i cells using
sonication and purified using a nickel sepharose 6FF column, the proteins were washed
and then eluted with 50mM cl pH8.0. 300mM NaCl, 1mM B-mercaptoethanol and
20mM lmidazole. Further purification was performed by affinity chromatography on a
HisTRAP HP column, eluting with a linear 0-500mM sodium de gradient, over 20
column volumes. Final purification was completed by Superdex 200 prep grade size
exclusion column. ed n was stored at -80C in 20mM HEPES pH 7.5 and
100mM NaCl. Protein identity was confirmed by peptide mass fingerprinting and
predicted molecular weight confirmed by mass spectrometry.
Protocol for omain BRD 2, 3 and 4 assays: All assay components were dissolved
in buffer composition of 50 mM HEPES pH7.4, 50mM NaCl and 0.5mM CHAPS. The final
concentration of bromodomain proteins were 100nM and the e peptide was 300nM,
these components are premixed and allowed to brate for 1 hour in the dark. 8 ul of
this reaction e was added to all wells containing 50n| of various concentrations of
test compound or DMSO vehicle (0.5% final) in Greiner 384 well black low volume
microtitre plates and incubated in dark for 60 mins at room temperature. 2ul of detection
mixture containing anti-6his XL665 labeled antibody and avidin labeled with
europium cryptate was added to all wells and a further dark incubation of at least 30mins
40 was performed. Plates were then read on the Envision platereader, (kex= 317nm, donor
XEM = 615nm; or XEM = 665nm; Dichroic LANCE dual). Time resolved
scent intensity measurements were made at both emission wavelengths and the
ratio of acceptor/donor was calculated and used for data analysis. All data was
normalized to the mean of 16 high and 16 low control wells on each plate. A four
parameter curve fit of the following form was then applied:
y=a+((b—a)/(1+(10"x/10"c)"d)
Where ‘a’ is the minimum, ‘b’ is the Hill slope, ‘c’ is the plC50 and ‘d’ is the m.
es 1 — 3 were tested in all of the BRD2, BRD3 and BRD4 assays described
above and were found to have a pleo in the range 6.5 - 7.5 in each assay.
Measurement of LPS induced lL-6 secretion from whole blood
Activation of monocytic cells by agonists of toll-like receptors such as bacterial
lipopolysaccharide (LPS) results in production of key inflammatory mediators including IL-
6. Such pathways are widely considered to be central to the hysiology of a range
of auto-immune and inflammatory disorders.
Compounds to be tested are diluted to give a range of appropriate concentrations
of which 1ul of the diluted stocks is added to a 96 well plate. Following addition of whole
blood (130ul) the plates are incubated at 37 degrees (5% 002) for 30 min before the
addition of 10u| of 2.8ug/ml LPS, diluted in complete RPMI 1640 (final concentration
=200ng/ml), to give a total volume of 140u| per well. After further incubation for 24 hours
at 37 s, 140u| of PBS are added to each well. The plates are sealed, shaken for 10
minutes and then centrifuged (2500rpm x 10 min). 100u| of the supernatant are removed
and lL-6 levels assayed by assay (typically by MesoScale Discovery technology)
either immediately or following storage at -20 degrees. Concentration response curves
for each nd was generated from the data and an |C50 value was calculated
Examples 1 and 2 were tested in this assay and were found to have a plC50 in the
range 6.0 - 7.0.
These data demonstrate that bromodomain inhibitors tested in the above whole
blood assay inhibited the production of key inflammatory mediator lL-6.
In vivo mouse model to demonstrate modulation of pro-inflammatory response
Male CD1 mice (25-30 g, n=4 per group) received a single iv bolus ion of LPS (100
ug/kg) via the tail vein 1 h after pre-treatment with a single oral administration of either
vehicle (1% (w/v) cellulose in sterile water) or the test compound (3, 10 and 30
mg/kg). Serial blood samples were obtained from the tail vein by direct ncture at
various time points up to 5 h post-LPS administration for analysis of lL-6 and the test
compound trations by Meso Scale ery (MSD) analysis and LC-MS/MS
respectively.
In vehicle control mice, i.v. LPS induced a time-dependent increase in serum lL-6
concentrations, while mice pre-treated orally with the compound of Example 2 (3, 10 and
mg/kg) had reduced maximum (Cmax) lL-6 levels by 46 %, 79 %, 73 % respectively,
and reduced total exposures (AUC) of lL-6 by 35 %, 70 %, 63 % respectively. This
40 reduction in lL-6 is comparable to the maximal reduction observed with the positive
control dexamethasone, Le: 73 % and 70 % ion in lL-6 Cmax and AUC, respectively.
These data demonstrate that the compound of Example 2 tested in the above
assay reduced LPS-induced systemic lL-6 levels in the mouse following a single oral
administration and consequently may have utility as an anti-inflammatory agent.
Oncology Cell Growth Assay
Human cell lines (n = 80 comprising cell lines bed in Table 2 below) were
ed in RPMI-1640 containing 10% fetal bovine serum, 1000 viable cells per well were
plated in 384-well black flat bottom polystyrene plates er #781086) in 48 pl of
culture media. All plates were placed at 5% C02, 37°C overnight. The following day one
plate was ted with CellTiter—Glo (CTG, a #G7573) for a time equal to 0 (T0)
measurement and compound (20 point titration from 14.7 uM to 7 pM) was added to the
remaining plates. The final concentration of DMSO in all wells was 0.15%. Cells were
incubated for 72 hours or the indicated time and each plate was developed with CellTiter-
Glo reagent using a volume equivalent to the cell culture volume in the wells. Plates were
shaken for approximately 2 minutes and chemiluminescent signal was read on the Analyst
GT (Molecular Devices) or EnVision Plate Reader n Elmer).
s are expressed as a percent of the T0 and plotted against the compound
concentration. The T0 value was normalized to 100% and represents the number of cells
at time of compound addition and the concentration response data were fit with a 4
parameter curve fit using XLfit software (model 205). The concentration that inhibited cell
growth by 50% (glC50) is the midpoint of the ‘growth window’ (between the T0 and DMSO
control). The Ymin - T0 value is determined by subtracting the T0 value (100%) from the
Ymin value (%) determined from the fit of the concentration response curve. Values from
the wells with no cells were subtracted from all samples for background correction.
The compound of Example 2 was tested in accordance with the above procedure
and found to have the glC50 as shown in Table 2.
Table 2
Cell line type
Multiple myeloma 1.1 to > 29326 nM (median 414
nM), with 15 out of 16 cell lines in the
rane1.1 to 2000 nM
Small cell lung cancer 76 to > 29326 nM (median 538
(SCLC) nM), with 35 of the 38 cell lines in the
rane 76 to 2500 nM
266- 847 nM
dline carcinoma
Neuroblastoma 25- 435 nM median 193 nM
Esophageal 208 — 1544 nM (median 759 nM)
The compound of Example 2 was also tested in accordance with an analogous procedure
using 96 well plates along with appropriate modifications to volumes and concentrations
that would be apparent to those skilled in the art. The nd of Example 2 was
tested and found to have the glC50 as shown in Table 3.
Table 3
Cell line type n
(number of
Acute monoc tic leukemia 123 nM
Acute promyelocytic
leukemia 141 nM
Cutaneous T cell
l mphoma 162 nM
Burkitt's l mphoma 181 — 807 nM
Chronic m eloid leukemia 776 nM
Breast cancer ductal 537 nM
Ovarian carcinoma 707 nM
These data demonstrate that the compound of Example 2 tested in the above
assay inhibited cell growth in a panel of oncology cell lines and may therefore have utility
in the ent of one or more s.
All publications, including but not limited to patents and patent applications, cited
in this specification are herein incorporated by reference as if each individual ation
were specifically and individually indicated to be incorporated by reference herein as
though fully set forth.
Claims (26)
1. A compound of formula (I) which is 4-(8-methoxy(1-methoxypropanyl) (tetrahydro-2H-pyranyl)-1H-imidazo[4,5-c]quinolinyl)-3,5-dimethylisoxazole or a salt thereof.
2. A compound according to claim 1, which is a compound of formula (IA), which is 4-(8-methoxy((R)methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5- c]quinolinyl)-3,5-dimethylisoxazole (IA) or a salt thereof.
3. A compound according to claim 1, which is a nd of formula (IB), which is 4-(8-methoxy((S)methoxypropanyl)(tetrahydro-2H-pyranyl)-1H-imidazo[4,5- c]quinolinyl)-3,5-dimethylisoxazole (IB) or a salt thereof.
4. A compound according to any one of claims 1 – 3 or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 and one or more pharmaceutically acceptable carriers, diluents or excipients.
6. A combination pharmaceutical product comprising a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 together with one or more other eutically active agents.
7. A nd or a ceutically acceptable salt thereof as defined in claim 4 for use in therapy.
8. A compound or a pharmaceutically able salt thereof as defined in claim 4 for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
9. A compound or a pharmaceutically acceptable salt thereof according to claim 8, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.
10. A compound or a pharmaceutically acceptable salt f according to claim 8, wherein the disease or condition is cancer.
11. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
12. A compound ing to claim 4 in the form of a free base.
13. A compound according to claim 4 in the form of a methanesulfonate salt.
14. A compound or a pharmaceutically acceptable salt thereof according to claim 10 wherein the cancer is selected from mia, NUT-midline carcinoma, multiple myeloma, neuroblastoma, Burkitt's lymphoma, al cancer, esophageal cancer, ovarian cancer, breast cancer and colorectal cancer.
15. The use of a compound or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of a chronic autoimmune and/or inflammatory condition.
16. The use of a compound or a pharmaceutically acceptable salt thereof as d in claim 4 in the manufacture of a medicament for the treatment of cancer.
17. The use of a nd or a pharmaceutically acceptable salt thereof as defined in claim 4 in the manufacture of a medicament for the treatment of leukaemia, NUT- e carcinoma, multiple myeloma, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal , ovarian cancer, breast cancer and colorectal cancer.
18. A compound according to claim 1 or a salt f, substantially as herein described or ified.
19. A nd according to claim 2 or a salt thereof, substantially as herein described or exemplified.
20. A compound according to claim 3 or a salt f, substantially as herein described or exemplified.
21. A pharmaceutical composition according to claim 5, substantially as herein described or exemplified.
22. A combination pharmaceutical product according to claim 6, substantially as herein described or exemplified.
23. A use according to claim 11, ntially as herein described or exemplified.
24. A use according to claim 15, ntially as herein described or exemplified.
25. A use according to claim 16, substantially as herein described or exemplified.
26. A use according to claim 17, substantially as herein described or exemplified.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1114103.3 | 2011-08-17 | ||
GBGB1114103.3A GB201114103D0 (en) | 2011-08-17 | 2011-08-17 | Novel compounds |
PCT/EP2012/065918 WO2013024104A1 (en) | 2011-08-17 | 2012-08-15 | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ620263A NZ620263A (en) | 2016-04-29 |
NZ620263B2 true NZ620263B2 (en) | 2016-08-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9861627B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1 H-imidazo[4,5-C]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor | |
EP2970127B1 (en) | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | |
US9029395B2 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
JP5856673B2 (en) | 7- (3,5-Dimethyl-4-isoxazolyl) -8- (methyloxy) -1H-imidazo [4,5-c] quinoline derivative | |
JP5926793B2 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
EP3191476B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
NZ620263B2 (en) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor |